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Introduction
Non-interventional studies (NIS) and "Anwendungsbeobachtungen" (AWB), which are included in this study class, have been a fixed and important component of medical research after the licensing of a medicine for decades. However, AWB are repeatedly the subject of public discussion as the criticism of this tool is almost as old as the AWB itself. The question which is repeatedly asked is whether the AWB really represents necessary healthcare research with licensed medicines or whether these are merely studies without any scientific value. The remuneration of the medical doctors for the work they provide in the scope of an AWB is also often the main focus of discussions: AWB are there to initiate prescriptions in the interests of the pharmaceutical industry and are therefore legalised corruption. "Anwendungsbeobachtungen" should therefore be banned [1] , [2] , [3] , [4] . However, this perspective largely masks out the development in the AWB field and fails to appreciate that an AWB is an important tool for generating knowledge on the pharmacovigilance of a medication and its licensed use. The importance of AWB as a tool for generating this knowledge is confirmed in the documentation of a scientific meeting at the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte; 2006 [5] ), in a publication of the Federal Ministry of Health [6] and in a statement on behalf of the Drug Commission of the German Medical Association [Arzneimittelkommission der deutschen Ärzteschaft] [7] . The aim to ensure quality and transparency of AWB was reached with successive statutory changes to Article 67 (6) Krankenkassen] as well as the responsible National Competent Authorities. In addition, the location, time, aims and observation plan of the study as well as the doctors participating in the study must be named. In this connection, the German Drug Law also includes: "According to its type and amount, remuneration which is paid to doctors for their participation in examinations according to sentence 1, is to be measured in such a way that there is no incentive to prescribe or recommend certain medicines." [8] Nearly at the same time as this topic developed, and partly even before the statutory regulations, the pharmaceutical industry acted independently in this regard. According to the guidelines of the "Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V." (FSA) Code of Conduct "Healthcare Professionals" [9] , the remuneration for NIS/AWB must be in an appropriate ratio to the services to be provided. In terms of the amount of remuneration, Article 19 (2) , No. 7 applies with the proviso that this is to be measured in a way which ensures there is no incentive to prescribe the medication. The remuneration must be measured based on the German Scale of Medical Fees [Gebührenordnung für Ärzte (GOÄ)] [10] and the execution of the study may not influence the therapy, prescription and procurement decisions. In 2007, the Association of Research-Based Pharmaceutical Companies (vfa) published its recommendations to improve further the quality and transparency of non-interventional studies [11] . These recommendations include quality assurance measures, particularly on the verification of the data collected and the transparency. In two surveys carried out amongst the member companies of the vfa, the implementation of the vfa recommendations in 2008 and 2010 was investigated and the results were compared [12] , [13] . Regular, internal quality control measures are applied in the planning, implementation and analysis phase [14] , [15] . Almost 1/3 of the companies carried out quality controls on site.
The results of the current survey amongst the member companies of the vfa on remuneration for AWB in June 2011 also show the consistent compliance with statutory guidelines as well as the implementation of the recommendations with regard to the payment of the study centres. Depending on the indication, the number of doctor/patient contacts varies; the documentation required also varies in line with this. The remuneration is calculated based on the German Scale of Medical Fees and the actual work provided by the study centre.
Background
The term "Anwendungsbeobachtung" (AWB) was established in 1986 by the then newly introduced para. 6 in Article 67 of the German Drug Law and since then, examinations with varying objectives using licensed medicines have been assigned the term AWB. The term was explicitly used in official regulations in 1989 in section 5.1 of the Drug Testing Guidelines [Arzneimittelprüfrichtlinien] [16] when counting the possible forms of scientific findings in the official evaluation of the effectiveness and harmlessness of drugs with a known agent. In comparison to this, AWB have been explicitly excluded from the regulatory scope of the Directive 2001/20/EC of the European Parliament and the Council from 4 th April 2001 on clinical trials [17] and therefore do not present any form of human clinical study pursuant to Article 4, para. 23, sentence 1 of the German Drug Law [8] . However, the German Drug Law does use the term non-interventional examination in Article 4, para. 23. This definition clearly demonstrates that AWB is to be considered as a subset of NIS in accordance with the respective definition in Directive 2001/20/EC Article 2 (c) ("non-interventional trial"). The purpose of an AWB is to gain information and experiences on the use of a certain, licensed medicine in everyday conditions, i.e. on risks and side effects and on the effectiveness of a medicinal product, which ultimately guarantees patient safety. In addition to this, a product monitoring obligation exists for the pharmaceutical entrepreneur as a manufacturer of drugs ("Public safety obligation"; see Article 84 of German Drug Law [8], Article 1 of the Product Liability Act [18] and Article 823 of the German Civil Code [19] ). This means an obligation to observe the circumstances of the use as well as the users (doctor and patient) of the drugs. AWB are particularly important as regards exercising this obligation to observe the product and consumer behaviour. Furthermore, in recent years the licensing authorities have been increasingly promoting "Post-Authorisation Safety Studies" (PASS) [20] or "Post-Authorisation Efficacy Studies" (PAES) [21] . Both licensing requirements can often also be met with NIS/AWB. According to Article 67 (6) of the German Drug Law [8], the National Association of Statutory Health Insurance Physicians, the National Association of Statutory Health Insurance Funds as well as the responsible National Competent Authorities are to be informed about all studies which collect information from the use of licensed or registered medicines, i.e. all AWB. In addition, the location, time, objective and observation plan of the AWB are to be indicated as well as the participating doctors. According to its type and amount, remuneration, which is paid to doctors for their participation in the studies according to sentence 1, is measured in such a way that there is no incentive to prescribe or recommend certain drugs. Should participating doctors provide services at the expense of statutory health insurance, the statements according to sentence 1 must also indicate the type and amount of remuneration paid to them as well as a copy of the contracts concluded with them. The statutory regulation therefore creates maximum transparency visa-vis the authorities and service providers in the statutory health insurance, including the amount of remuneration paid. Alongside the legislator, the "Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V." (FSA), which was founded in 2004 and to which all regular member companies of the vfa belong, has been dealing with the topic of remunerating AWB from the very beginning of its work. According to the FSA Code of Conduct "Healthcare Professionals" [9] , the remuneration for AWB must be in an appropriate ratio to the services to be provided. As regards the amount of remuneration, Article 19, para. 2, No. 7 applies with the proviso that the remuneration is measured in such a way to ensure there is no incentive to prescribe a medicine. Therefore, AWB may not influence medical prescribing behaviour. Given that conducting an AWB is associated with additional work (e.g. separate documentation; patient clarification about the use of the health data collected), appropriate remuneration is justified and authorised. The legislator does not mention concrete figures. The payment must be based on the "extent of the respective work". This regulation should exclude AWB being abused to influence therapy, regula-tion and procurement decisions [22] . Varying amounts of remuneration can be explained by different requirements for the participating study centres according to the field of indication and the associated documentation work. The FSA made an important decision with regards to the amount of remuneration for AWB:
• The AWB were conducted primarily in oncology (31), neurology (15) and rheumatoid arthritis (10), but also AWB were performed e.g. in multiple sclerosis, hypertension and in the field of virology (HIV) -see Table 1 for details. 
Remuneration
The recommendations of the FSA/vfa as well as the German Drug Law stipulate that "remuneration which is paid to doctors for their participation in examinations is to be measured in such a way that ensures there is no incentive to prescribe or recommend a certain drug" [8], [9] . All companies stated that they used the Scale of Medical Fees from 2002 [10] , in accordance with the FSA Code of Conduct, as a basis for calculating the remuneration.
The results of the survey show that the amount of remuneration is based on the actual service provided by the study centre, which comprises the work of the doctor and non-medical staff:
• Documentation work with the help of the record sheets;
• Time spent informing/notifying the participating patient or the patient addressed about possible participation, particularly about data protection aspects with regard to the transfer or processing of data collected by the client; • Explanations, for example, of the patient surveys, collecting these and checking to ensure they are complete by the client; • Time spent carrying out a quality control of the data collected by the client, in cases in which a quality control is actually carried out.
None of the companies provided for remuneration without considering the documentation and informative work actually provided. In all cases, the remuneration was paid in accordance with the fully documented visits and/or complete documentation surveys, whereby the remuneration was dependent on the duration of the AWB and the complexity of the documentation.
The survey recorded AWB with documentation requirements of between 8 and 490 DIN A4 pages per complete patient documentation. This range shows the very different approaches (and the differing level of work required for the doctor/the study centre as a result) between the individual AWB. Accordingly the remuneration was also different; from € 25 in an AWB with a documentation requirement of 8 pages with one doctor/patient contact and € 2,400 in an AWB with 490 pages of complete documentation with seven visits in 36 months. This AWB not only examined the use of the drug but also the resources necessary and the specific costs for the standard therapy (therapies) in the indication examined in Germany. This involved approx. 70 pages of documentation per doctor/patient contact and also contained questionnaires for patients and involved relatives. The observation period in AWB is also very different. The range recorded varied between one doctor/patient contact (visit), right through to examinations which monitor patients with a chronic illness over 15 years. In some answers (5), it was highlighted that in case of incomplete documentation, no remuneration for the doctor/study centre is stipulated, i.e. the remuneration is only paid with complete patient documentation. Table 2 presents 5 AWB with the highest and lowest remuneration. Overall on average for 126 AWB and complete documentation of a patient a reward of € 339 was paid, this documentation expenditure encompasses 41 pages of documentation and 4 doctor-patient contacts in general. Pharmazeutischen Industrie] (BPI) presented its "Points to Consider" for AWB [29] in 2009. In vfa surveys as well as in peer reviewed articles [12] , [13] quality control and quality assurance measures are described, for example when verifying the data collected, during data entry and data acquisition as well as for the statistical analysis [14] , [31] . These articles and publications indicate that a high degree of trust in the validity of the data recorded in NIS/AWB and the results obtained from NIS/AWB is justified [15] . In addition, publishing information on the conduct of NIS/AWB together with the study results in publicly accessible internet portals serves to ensure transparency in this research sector. Study results are to be presented in accordance with the recommendations of the STROBE statement (Strengthening the Reporting of Observational Studies in Epidemiology) [30] . The return rate in this survey was at 47% and included a vast majority of major pharmaceutical companies within the vfa. However, the survey results deem to be representative based on the number of AWB conducted by these companies.
The survey results show that the remuneration of AWB in the member companies of the vfa is generally based on the time required at the study centre and that it applies to the standards of the Scale of Medical Fees [10] . In accordance with no. 85 of the attachment of the Scale, all companies are calculating with a fee of € 75.00 per working hour. The parameters evaluated within this survey, i.e. compensation for a full set of patient documentation (in particular the number of case report sheets together with the number of doctor-patient contacts), there is no evidence for any deviation from this standard Higher documentation requirements may be caused and in most cases justified by the routine medical behaviour in a particular indication and associated with the number of doctor/patient contacts This is true in particular in indications such as oncology, neurodegenerative and mental illnesses and infectious diseases such as HIV. Overall, the results of the survey confirm that the amount of remuneration is based on the actual work provided by the study centre or the medical doctor. Differences in the remuneration may result from partly more extensive documentation requirements, the informed consent process as well as participation in quality assurance meas-ures such as source data verification at the study centre or the participation in study meetings. 
